Key facts
- It has raised $6.7M; the latest was Seed Round ($6.7M) in Oct 2025.
- Notable investors include NFX, Accelerate@Babraham, Cocoa Ventures, Eka Ventures, Lavender Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cyclana Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Cyclana Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cyclana Bio
Developer of a therapeutic discovery platform intended to uncover disease mechanisms in women's health. The company's platform utilizes advanced tissue and matrix biology techniques, including the analysis of collected human menstrual fluid, to build first-of-a-kind physiological assays of the diseased tissue niche and better stratify complex health conditions, enabling therapeutic researchers to pinpoint the precise disease-driving biological targets necessary for developing novel and effective treatment options for women suffering from severely underserved conditions like endometriosis.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- cyclanabio.com/
- Ownership
- Privately Held (backing)
Cyclana Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyclana Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyclana Bio in its N-PORT filings yet. We sweep new filings monthly.